St. Jude Medical has some compelling clinical and real-world data that it will use to gain better reimbursement coverage for its implantable heart-failure treatment device.

Arundhati Parmar

 

St. Jude Medical has had a tough go of getting reimbursement coverage for the pricey product that is CardioMEMS, the company's novel implantable heart failure management device.

In its most recent quarterly earnings conference call, St....

February 12th, 2016
0

Abbott's Take on Emerging Markets

"Every morning we get up, we see CNBC. Everybody brings their hands about China, but whether China is 7% growth or 6% growth, 6% is way bigger than the rest of the world. It's a fundamentally strong market for us as [are] practically all of these emerging markets.

Now, the oil-based economy, the ones we were extremely dependent on oil, take Venezuela—okay, there are different stories. And the volatility, unreliability and sustainable market there is different than just about anywhere in the world . . . 

. . .  As many of you know, market conditions in...

February 12th, 2016
0

C.R. Bard's Take on Emerging Markets

"We haven't really seen a change from the trends that we've seen. Clearly, we pay attention to what others are seeing and feeling in emerging markets. I think it might be kind of the mix of the geographies where we're strong and have a sizeable presence and some of the geographies that seem to be causing others more of an issue; either it's the mix of our offering in those geographies that don't seem to be impacted and/or we're not very strong in some of those other geographies."

—Timothy Ring, C.R. Bard chairman and CEO,...

February 12th, 2016
0

BD's Take on Emerging Markets

"The first quarter growth rate in emerging markets reflects a very difficult comparison to the prior year period for both the BD and CareFusion legacy businesses and a moderation of growth in China. China growth for the first quarter was 4.5%, compared with growth of over 23% in the first quarter of last year. This difficult comparison was in line with our expectations.

Beyond the difficult comparison, we also experienced the continued slowdown of capital spending in diagnostic systems, which resulted in inventory adjustments . . . While there are pockets of pressure, millions of patients...

February 12th, 2016
0

Varian Medical Systems' Take on Emerging Markets

"Let me kind of underscore one of the things I had pointed out in the call weak [in] Japan, weak [in] Europe. The emerging markets weak [in] Russia for sure, but we had some Latin America activity that wasn’t too bad. China as I mentioned was down. But we kind of have a timing issue with that . . . So we actually think China is going to be okay.

The long term is where we still think these markets are going to grow we’ve built that market development team . . . But we were clearly looking at this...

February 12th, 2016
0

Johnson & Johnson's Take on Emerging Markets

"Look, I think what we would say overall is we continue to see let's say a slightly increasing positive trend. So we saw hospital admissions I believe up around 2%. We saw surgical procedures up a little over 1% in the U.S. That's the most recent data that we have.

If we go outside the U.S. we think rates in Europe have been pretty steady. And even in the markets in which we compete most significantly in the developing markets, we haven't seen a major impact from secular shifts. Perhaps in China some but not dramatic. And then putting that into the context...

February 12th, 2016
0

Baxter's Take on Emerging Markets

"Well, as you read the same headlines I do read, there is a contraction in some of the major—the larger emerging market economies. Very different in nature between China and Brazil and Russia, but nonetheless, we do 25% of our business in those regions. I think one particular thing about our business is that we are not a physician preferred product in those regions, and we are a hospital necessity. So we're talking about infusion, we're talking about dialysis, and those products are needed. So we have seen price pressure in those markets, but we probably saw that ahead of many...

February 12th, 2016
0

In recent months, economists and financiers have voiced concerns about the health of China and other emerging market economies. What do potentially shaky markets mean for the largest medical device makers?

Low oil prices, volatility in the Chinese stock market, and geopolitical instability are all factors behind the economic uncertainty in emerging markets. Economists have their eye on the BRIC countries, as well as other developing economies, as they monitor for signs of slowing growth.

What does this mean for the medical device and diagnostics industry? Many of the largest medtech manufacturers have placed emphasis on the emerging markets in recent...

February 12th, 2016
0

Don’t let your next medical innovation fall victim to the intricacies of the healthcare system.

Jamie Hartford

The medical device industry has seen many breakthrough devices that save and improve lives while at the same time making lots of money for the companies that developed them. On the flip side are the products that seem promising at first but never quite pan out commercially.

So what is it that separates the wheat from the chaff?

If you ask Betsy Gross, vice president of healthcare economics and reimbursement at healthcare equipment company Intersect ENT, it’s their companies’ reimbursement strategies.

“Unfortunately, there’s a graveyard of brilliant technology that never makes it to market because all of...

February 11th, 2016
0

In a new report, Public Citizen rails against a legislative proposal in the 21st Century Cures Act that would encourage FDA to approve high-risk medical devices based only on data published in peer-reviewed journals.

Marie Thibault

Public Citizen opposes a proposal to encourage FDA approval of high-risk medical devices using just peer-reviewed journal data.

The advocacy group has released a report outlining its objections to a section of the 21st Century Cures Act that would specifically include studies in peer-reviewed journals as "valid scientific evidence" suitable for FDA to determine device effectiveness.

According to its report, "A...

February 11th, 2016
0